Form 4 for BIIB Biogen
Accepted 2026-02-17 00:00:00 ET · period of report 2026-02-12 · accession 0000875045-26-000033 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2026-02-17 | 2026-02-12 | BIIB | Murphy Nicole | Head of Pharm Ops, Tech | P - Purchase | $195.04 | +3 | 19.6K | +0.0% | +$585.12 |
| D | 2026-02-17 | 2026-02-13 | BIIB | Murphy Nicole | Head of Pharm Ops, Tech | A - Grant | $0.00 | +10.6K | 10.6K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-02-12 | P | A | 3 | $195.04 | 19,611.04 | D | — | — | |
| 2 | Derivative | Restricted Stock Unit | 2026-02-13 | A | A | 10,560 | $0.00 | 10,560 | D | $0.00 · — to 2029-02-13 | 10,560 Common Stock | (F1) The restricted stock units vest in three equal yearly installments beginning on the first anniversary of the grant date of February 13, 2026. |